| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10006718 | HBV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS10037085 | HBV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS10027170 | HBV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS10016254 | HBV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30014318 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30017181 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30088810 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30035717 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30035718 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
| TVIS30035719 | HIV | ENSG00000175198.17 | protein_coding | PCCA | No | No | 5095 | P05165 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PCCA |
|---|---|
| DrugBank ID | DB00121 |
| Drug Name | Biotin |
| Target ID | BE0000492 |
| UniProt ID | P05165 |
| Regulation Type | cofactor |
| PubMed IDs | 17139284; 17016423; 12385775; 9311592; 15623830; 16772434 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Clavero S, Martinez MA, Perez B, Perez-Cerda C, Ugarte M, Desviat LR: Functional characterization of PCCA mutations causing propionic acidemia. Biochim Biophys Acta. 2002 Nov 20;1588(2):119-25.@@Cherbonnel-Lasserre CL, Linares-Cruz G, Rigaut JP, Sabatier L, Dutrillaux B: Strong decrease in biotin content may correlate with metabolic alterations in colorectal adenocarcinoma. Int J Cancer. 1997 Sep 4;72(5):768-75.@@Vlasova TI, Stratton SL, Wells AM, Mock NI, Mock DM: Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood. J Nutr. 2005 Jan;135(1):42-7.@@Hassan YI, Zempleni J: Epigenetic regulation of chromatin structure and gene function by biotin. J Nutr. 2006 Jul;136(7):1763-5. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Biotin and derivatives |
| SMILES | [H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2 |
| Pathways | Mitochondrial Complex II Deficiency; 3-Methylglutaconic Aciduria Type III; 2-Ketoglutarate Dehydrogenase Complex Deficiency; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Isovaleric Aciduria; Pyruvate Carboxylase Deficiency; Warburg Effect; Isobutyryl-CoA Dehydrogenase Deficiency; Biotin Metabolism; Fructose-1,6-diphosphatase Deficiency; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Propionic Acidemia; Transfer of Acetyl Groups into Mitochondria; Malonic Aciduria; 2-Hydroxyglutric Aciduria (D and L Form); 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Congenital Lactic Acidosis; 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency; Fumarase Deficiency; Succinic Semialdehyde Dehydrogenase Deficiency; Alanine Metabolism; Methylmalonic Aciduria; 3-Methylglutaconic Aciduria Type IV; Lactic Acidemia; Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease; Primary Hyperoxaluria Type I; Triosephosphate Isomerase; The Oncogenic Action of 2-Hydroxyglutarate; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease |
| PharmGKB | PA448625 |
| ChEMBL | CHEMBL857 |
